• +1-646-491-9876
    • +91-20-67278686

    Search

    Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

    Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689396
    • Category Healthcare
    • No. of Pages 67
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

    Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 4, 6, 3, 3 and 1 respectively.

    Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Onychomycosis (Tinea Unguium) - Overview
    Onychomycosis (Tinea Unguium) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Onychomycosis (Tinea Unguium) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
    Almirall SA
    Arno Therapeutics Inc
    Blueberry Therapeutics Ltd
    Dermala Inc
    Eisai Co Ltd
    Helix BioMedix Inc
    Hexima Ltd
    Meiji Seika Pharma Co Ltd
    Moberg Pharma AB
    NAL Pharmaceuticals Ltd
    Nihon Nohyaku Co Ltd
    Novabiotics Ltd
    Novan Inc
    Viamet Pharmaceuticals Inc
    Onychomycosis (Tinea Unguium) - Drug Profiles
    AR-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BB-0305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BB-2603 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Onychomycosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ELS-160 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fosravuconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HB-1275 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HXP-124 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    luliconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ME-1111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAL-3210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NP-213 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-3058 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-208 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    terbinafine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    terbinafine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VT-1161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Onychomycosis (Tinea Unguium) - Dormant Projects
    Onychomycosis (Tinea Unguium) - Discontinued Products
    Onychomycosis (Tinea Unguium) - Product Development Milestones
    Featured News & Press Releases
    Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
    Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
    Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
    Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
    Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
    May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015
    Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
    Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015
    Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit
    Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
    Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
    Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
    Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
    Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
    Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics Inc, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2017
    Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
    Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017
    Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Almirall SA
    Arno Therapeutics Inc
    Blueberry Therapeutics Ltd
    Dermala Inc
    Eisai Co Ltd
    Helix BioMedix Inc
    Hexima Ltd
    Meiji Seika Pharma Co Ltd
    Moberg Pharma AB
    NAL Pharmaceuticals Ltd
    Nihon Nohyaku Co Ltd
    Novabiotics Ltd
    Novan Inc
    Viamet Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//onychomycosis-tinea-unguium-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//onychomycosis-tinea-unguium-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//onychomycosis-tinea-unguium-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments